This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matteelli, A.
Right arrow Articles by Gulletta, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matteelli, A.
Right arrow Articles by Gulletta, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2005, p. 663-667, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.663-667.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Mefloquine versus Quinine plus Sulphalene-Pyrimethamine (Metakelfin) for Treatment of Uncomplicated Imported Falciparum Malaria Acquired in Africa

Alberto Matteelli,1* Nuccia Saleri,1 Zeno Bisoffi,2 Giampietro Gregis,3 Giovanni Gaiera,4 Raffaella Visonà,5 Simona Tedoldi,1 Carla Scolari,1 Stefania Marocco,2 and Maurizio Gulletta1

Institute of Infectious and Tropical Diseases, University of Brescia, Brescia,1 Centre for Tropical Medicine, Sacro Cuore Hospital, Negrar,2 Clinic of Infectious Diseases, San Anna Hospital, Como,5 Clinic of Infectious Diseases, IRCCS San Raffaele, Milan,4 Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy3

Received 16 July 2004/ Returned for modification 19 August 2004/ Accepted 28 September 2004

We conducted a multicenter, randomized, open-label trial to compare mefloquine with a 3-day quinine plus sulphalene-pyrimethamine (SP) regimen for the treatment of imported uncomplicated malaria acquired in Africa. The end points of the study were efficacy, tolerability, and length of hospital stay. From July 1999 to February 2003, 187 patients were enrolled in five centers in Italy, of whom 93 were randomized to receive mefloquine (the M group) and 94 were randomized to receive quinine plus SP (the QSP group). Immigrants and visiting relatives and friends represented 90% of the cases and were mainly from western African countries. A slightly increased proportion of cases in the QSP group had abnormal alanine aminotransferase levels at the baseline. The early cure rate was similar in the two groups: 98.9% (confidence interval [CI] = 97 to 100%) in the M group and 96.8% (CI = 93 to 100%) in the QSP group. The extended follow-up was completed by 135 subjects (72.2%), and no case of recrudescence was detected. There were no differences in the parasite clearance time, but patients in the M group had shorter mean fever clearance time (35.9 h versus 44.4 h for the QSP group; P = 0.05) and a shorter mean hospital stay (3.9 days versus 4.6 days for the QSP group; P = 0.007). The overall proportions of reported side effects were similar in the two groups, but patients in the M group had a significantly higher rate of central nervous system disturbances (29.0% versus 9.6% for the QSP group; P < 0.001).

* Corresponding author. Mailing address: Institute of Infectious and Tropical Diseases, University of Brescia, Brescia 25125, Italy. Phone: 39.030.3995671. Fax: 39.030.303061. E-mail: amatteelli{at}bsnet.it.

Antimicrobial Agents and Chemotherapy, February 2005, p. 663-667, Vol. 49, No. 2
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.2.663-667.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»